In short
This article discusses a Phase III clinical trial investigating the use of INM004, a drug containing Equine Immunoglobulin F(Ab')2 Fragments Targeting Shiga Toxin, for treating children with Hemolytic Uremic Syndrome (HUS) caused by Shiga toxin-producing Escherichia coli (STEC). The study aims to assess the efficacy and safety of INM004 in improving renal function and reducing complications associated with STEC-HUS in pediatric patients.
At a glance
- Study Type
- Phase III, multicenter, randomized, double-blind, adaptive-designed, placebo-controlled clinical trial
- Medication
- INM004 (Equine Immunoglobulin F(Ab')2 Fragments Targeting Shiga Toxin)
- Condition
- Hemolytic Uremic Syndrome associated with Shiga toxin-producing Escherichia coli (STEC-HUS)
- Target Population
- Children aged 9 months to 18 years
- Primary Objective
- Evaluate efficacy in improving renal function
- Secondary Objectives
- Assess impact on mortality, extrarenal complications, hematological parameters, hospital stay duration, and safety
- Dosage
- Two doses of 4 mg/kg, administered 24 hours apart
- Administration Route
- Intravenous infusion
- Primary Endpoint
- Time to recovery of renal function during the acute phase (within 28 days)
- Key Secondary Endpoints
- Recovery of kidney function at 90 days, incidence of dialysis, mortality rate
What is INM004?
INM004, also known as "ANTI SHIGA TOXIN" or "Shiga antitoxin," is a new medication being studied for the treatment of a serious condition called Hemolytic Uremic Syndrome (HUS) in children. The active ingredient in INM004 is equine immunoglobulin F(ab')2 fragments targeting Shiga toxin. This means it's made from parts of antibodies from horses that are specifically designed to fight against a toxin called Shiga toxin.
What is Hemolytic Uremic Syndrome (HUS)?
Hemolytic Uremic Syndrome (HUS) is a serious condition that can occur after an infection with certain types of E. coli bacteria that produce Shiga toxin. These bacteria are called Shiga toxin-producing Escherichia coli (STEC). HUS can cause damage to the kidneys and other organs. It typically affects children and can be life-threatening if not treated promptly.
How INM004 Works
INM004 is designed to target and neutralize the Shiga toxin produced by certain E. coli bacteria. By doing this, it aims to reduce the harmful effects of the toxin on the body, particularly on the kidneys. The medication is given as an intravenous infusion, which means it's delivered directly into the bloodstream through a vein.
Clinical Trial Details
A Phase III clinical trial is currently underway to evaluate how well INM004 works in children with HUS caused by Shiga toxin-producing E. coli. Here are some key details about the trial:
- It's a randomized, double-blind, placebo-controlled study, which means some participants will receive INM004 while others will receive a placebo (a substance with no active medication).
- The study aims to enroll about 220 participants.
- Participants will be randomly assigned to receive either INM004 or a placebo.
- The medication is given as two doses of 4 mg/kg, 24 hours apart.
Who Can Participate in the Trial?
The trial is looking for children who meet specific criteria. Some key points include:
- Age: Children between 9 months and 18 years old.
- Diagnosis: Must have a clinical diagnosis of STEC-HUS (HUS caused by Shiga toxin-producing E. coli).
- Recent symptoms: Must have had diarrhea within 10 days before being diagnosed with STEC-HUS.
There are also several conditions that would prevent a child from participating in the trial, such as certain medical conditions or recent participation in other clinical trials.
Potential Benefits of INM004
The researchers are studying INM004 to see if it can provide several benefits for children with HUS, including:
- Improving kidney function.
- Reducing the risk of death.
- Preventing or reducing complications in other organs.
- Improving blood-related issues associated with HUS.
- Reducing the length of hospital stay.
Safety Considerations
As with any new medication, safety is a crucial concern. The trial will carefully monitor the safety of INM004. It's important to note that because INM004 is made from horse antibodies, people with a history of allergic reactions to horses or horse-derived products are not eligible to participate in the trial.
This clinical trial represents an important step in developing a potential new treatment for children with HUS. If successful, INM004 could offer a new option for managing this serious condition.